Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

CIRM Grant of $6.85 million supports the first-in-human clinical study evaluating the safety and efficacy of EBT-101 in participants people living with HIV